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A B S T R A C T   
Background: Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors 
(RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the 
prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID- 
19 pandemic, which was the aim of the present study. 
Methods: STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the 
ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI 
therapy at admission. 
Results: Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No 
difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% 
vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 
[0.51–0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33–0.74], P 
= 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI 
therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084–0.14], p 
< 0.0001), confirmed after adjustment in both periods. Among the 62 SARSCoV-2 positive patients, RASI 
therapy, both at admission or in-hospital, showed no prognostic effect. 
Conclusions: This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 
infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital 
RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital 
RASI therapy showed no impact on survival.   
1. Background 
The global pandemic of coronavirus disease 2019 (COVID-19) has 
dramatically impacted on healthcare and its effects are ongoing. As of 8 
September 2020, more than 27 million cases of COVID-19 have been 
reported in more than 185 countries and territories, resulting in over 
90,000 deaths, especially in Europe, the United States and Latin 
America. 
Large interests have been focused on a potential harmful effect of 
angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin re-
ceptor blockers (ARBs), the so-called renin-angiotensin system in-
hibitors (RASI) in infected patients. These therapies were suspected to 
condition the ability of SARS-CoV-2 to infect the cells through an 
upregulation of angiotensin-converting enzyme 2 (ACE2), the receptor 
for SARS-CoV-2 cell entry [1,2]. The increased expression of ACE2 under 
RASI was suspected to increase the patient’s susceptibility to COVID-19, 
and the large prevalence of hypertension among patients affected by 
COVID-19 has raised the fear of contagion and worsened the clinical 
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outcome among patients with cardiovascular disease. This might have 
affected prescription and the patients’ compliance to such therapy. 
Professional societies and opinion leaders have overcome this uncer-
tainty by recommending that patients receiving ACE-inhibitors and 
ARBs should continue taking their medication until the results of pow-
ered outcome studies become available [3–5]. 
Data emerging from selected cohorts have suggested, to date, that 
ACEI/ARB use was not associated with increased risk of COVID-19 or 
worse outcomes among those with infection [6–8]. However, no data 
have been, so far, reported in patients suffering from ST-elevation 
myocardial infarction (STEMI), a very high-risk population with a 
large use of RASI. 
The International Study on Acute Coronary Syndromes – ST Eleva-
tion Myocardial Infarction (ISACS-STEMI) COVID-19 was established in 
response to the emerging outbreak of COVID-19, aiming at providing a 
European snapshot and estimating the true impact of the COVID-19 
pandemic on the treatment and outcome of STEMI patients treated by 
PPCI. The aim of this analysis was to investigate whether the use of RASI 
at the time of hospitalization was associated with the susceptibility to 
COVID-19 and with an increased mortality risk. 
2. Study design and population 
Our study population is represented by patients enrolled in the 
ISACS-STEMI COVID-19 (NCT 04412655), a multicenter registry 
including STEMI patients enrolled by 77 high-volume European primary 
percutaneous coronary intervention (PCI) centers, which was conducted 
to compare STEMI patients treated from March 1st until April 30th of 
2019 with those admitted within the same period of 2020. 
We collected demographic, clinical, procedural data, data on total 
ischemia time, door-to-balloon time, referral to primary PCI facility, PCI 
procedural data and in-hospital mortality. Follow-up was performed for 
the duration of the hospitalization. The diagnosis of SARS-CoV-2 
infection was performed by molecular nasal/oropharyngeal swab, ac-
cording to the single center protocols. The study was approved by the 
Ethical Committee of AOU Maggiore della Carità, Novara. 
2.1. Patients and public involvement 
Not applicable since recruitment was retrospective and anonymous. 
2.2. Statistics 
Data analysis was performed by using SPSS Statistics Software 23.0 
(IBM SPSS Inc., Chicago, Illinois) and supervised by an experienced in-
dependent statistician (GC). Quantitative variables were described using 
median and interquartile range. Absolute frequencies and percentages 
were used for qualitative variables. ANOVA or Mann-Whitney and the 
chi-square test were used for continuous and categorical variables, 
respectively. Normal distribution of continuous variables was tested by 
the Kolmogorov-Smirnov test). 
As previously described [9], a propensity score analysis was per-
formed in order to overcome the potential bias related to the differences 
in baseline characteristics. For each patient, a propensity score indi-
cating the likelihood of having chronic or in-hospital RASI administra-
tion was calculated by the use of forward logistic regression analysis that 
identified variables independently associated with RASI prescription. 
The discriminatory capacity of the propensity score was assessed by 
the area under the ROC curve (c-statistic) as an index of model perfor-
mance [10]. On the basis of the propensity score, the population was 
divided in four groups (from the lowest to the highest probability to 
have RASI prescribed) by the use of quartiles. The impact of RASI on 
mortality and SARS-2 positivity was evaluated for each quartile, 
separately. 
Furthermore, multivariable logistic regression analyses were per-
formed to identify the association of RASI with in-hospital mortality and 
SARS-CoV-2 infection after adjustment for baseline confounding factors 
between the two groups, including the propensity score. All variables of 
interest (set at a P-value < 0.1) were entered in block into the model. A p 
< 0.05 was considered statistically significant. The data coordinating 
center was established at the Eastern Piedmont University, Novara, 
Italy. 
3. Results 
The study population comprises a total of 6095 STEMI patients un-
dergoing mechanical reperfusion, in whom complete demographic, 
clinical, procedural, and outcome data were available as well as infor-
mation regarding chronic RASI therapy at admission. Median age was 64 
[55–73] years, including 4517 males (74.1%). Table 1 shows the base-
line characteristics of patients with versus without chronic RASI therapy 
at admission, according to the year of treatment. Several differences 
were observed in baseline characteristics, similarly observed in 2019 
and 2020. Patients on RASI were older, more often female, suffering 
from diabetes, hypertension, hypercholesterolemia, previous STEMI, 
previous coronary revascularization, but less often active smokers. Pa-
tients on RASI had a longer door-to-balloon and total ischemia time. 
Patients on RASI had less often out-of-hospital cardiac arrest and 
cardiogenic shock, especially in 2020 (7.5% vs 10.2%, p = 0.02). No 
difference was observed between 2019 and 2020 in terms of RASI 
discontinuation after hospital admission (information available in 5388 
patients: 21.2% in 2019 vs 20.6% in 2020). 
Angiographic and procedural characteristics are shown in Table 1S. 
RASI patients underwent less frequently PPCI via a radial approach and 
had less often DES implanted, but presented more often with in-stent 
thrombosis and multivessel disease. The duration of follow-up (hospi-
talization) was 5 [3–7] days. No difference was observed for in-hospital 
mortality (6.0% vs 5.7%, OR [95% CI] = 0.94 [0.76–1.17], p = 0.59,  
Fig. 1). Fig. 1S shows the impact of chronic RASI therapy in each quartile 
of the propensity score. In most of them, chronic RASI therapy was 
associated with a trend in beneficial effects. In fact, after adjustment for 
all baseline confounding factors, including the propensity score, chronic 
RASI therapy was associated with lower mortality (adjusted OR [95% 
CI] = 0.67 [0.51–0.89], p = 0.005). In the analysis restricted to 2020, we 
confirmed the benefits in mortality (adjusted OR [95% CI] = 0.5 
[0.33–0.74], P = 0.001). Furthermore, between patients with vs. 
without chronic RASI therapy, no difference was observed in the prev-
alence of SARS-CoV2 infection (n = 62) (2.5% vs 2.1%, OR [95% CI] =
1.19 [0.72–1.98], p = 0.5, adjusted OR [95% CI] = 1.06 [0.56–2.0], p =
0.86) (Fig. 2). 
A further analysis was conducted to evaluate the impact of in- 
hospital RASI therapy (data available in 5388 patients). Demographic 
and clinical characteristics are shown in Table 2. Patients receiving RASI 
during hospitalization were younger and more often males, more often 
diabetics (especially in 2019), active smokers, hypercholesterolemic, 
and had more often a family history of CAD and anterior STEMI; 
nevertheless, these patients less often presented with out-of-hospital 
cardiac arrest or cardiogenic shock. Angiographic and procedural 
characteristics are shown in Table 2S. Patients receiving RASI during 
hospitalization had more often radial access, LAD as culprit, post-
procedural TIMI 3 flow, DAPT, while they displayed less often proximal 
lesion locations). In-hospital RASI therapy was associated with a 
significantly lower mortality (2.1% vs 16.7%, OR [95% CI] = 0.11 
[0.084–0.14], p < 0.0001) (Fig. 3). The benefits were confirmed in 
almost all the quartiles of the propensity score (Fig. 2S) and confirmed 
after the adjustment for all the confounding baseline characteristics, 
including the propensity score (adjusted OR [95% CI] = 0.15 
[0.11–0.21], p < 0.001). In the analysis restricted to patients treated in 
2020, we confirmed the survival benefits in mortality with in-hospital 
RASI therapy (adjusted OR [95% CI] = 0.15 [0.10–0.22], p < 0.001) 
(Fig. 3). The prevalence of SARS-CoV2 infection (n = 62) was signifi-
cantly lower among patients receiving RASI during hospitalization 
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(1.7% vs 4.5%, OR [95% CI] = 0.37 [0.22–0.62], p < 0.001, adjusted 
OR [95% CI] = 0.39 [0.23–0.66], p = 0.001) (Fig. 2). 
Among the 62 SARSCoV-2 positive patients, both chronic RASI (OR 
[95% CI] = 1.95 [0.65–6.0], p = 0.23, adjusted OR [95% CI] = 1.41 
[0.29–6.78], p = 0.67 or in-hospital RASI therapy (OR [95% CI] = 0.5 
[0.16–1.56], p = 0.24; adjusted OR [95% CI] = 0.9 [0.2–4.1], p = 0.89) 
had no significant negative effect on survival (Fig. 3S). 
4. Discussion 
The main finding of the present study is that among STEMI patients 
undergoing mechanical reperfusion during the COVID-19 pandemic, 
RASI therapy at admission had no negative impact on survival or the 
prevalence of SARSCoV-2 infection. In-hospital RASI therapy was even 
associated with a significantly lower mortality and less often with 
SARSCoV-2 infection. Finally, among SARSCoV-2 positive patients, both 
chronic RASI therapy before admission and in-hospital RASI did not 
have a significant negative impact on survival. 
ACEI/ARB treatment has been studied in various cardiovascular 
disease and was found to be efficacious in reducing death and adverse 
cardiovascular end points [11–14], with significant benefits observed 
Table 1 
Baseline demographic and clinical characteristics according to chronic RASI therapy at admission.   
OVERALL POPULATION (N =
6095)  
YEAR 2019 (N = 3389)  YEAR 2020 (N = 2706)  
RASI (n =
2441) 
















Age (median, IQR) 67 [58–75] 62 [53–71] <
0.001 
67 [58–75] 62 [53–71] <
0.001 
67 [59–75] 62 [53–71] <
0.001 
Age > 75 year – n. (%) 664 (27.2) 633 (17.6) <
0.001 
373 (27.1) 358 (17.8) <
0.001 
291 (27.3) 275 (16.8) <
0.001 
Male gender – n. (%) 1801 (71.3) 2870 (75.8) <
0.001 
969 (70.5) 1527 (75.8) 0.001 765 (71.8) 1256 (76.6) 0.005 
Diabetes Mellitus- n (%) 758 (31.1) 568 (15.5) <
0.001 
428 (31.1) 316 (15.7) <
0.001 
330 (31) 252 (15.4) <
0.001 
Hypertension- n (%) 2170 (88.9) 1148 (31.4) <
0.001 
1234 (89.7) 634 (31.5) <
0.001 
936 (87.8) 514 (31.3) <
0.001 
Hypercholesterolemia - n (%) 1225 (50.2) 1350 (36.9) <
0.001 
679 (49.4) 739 (36.7) <
0.001 
546 (51.2) 611 (37.3) <
0.001 
Active Smokers – n (%) 895 (36.7) 1639 (44.9) <
0.001 
514 (37.4) 901 (44.7) <
0.001 
381 (35.7) 738 [45] <
0.001 
Family History of CAD - n (%) 550 (22.5) 859 (23.5) 0.37 319 (23.2) 479 (23.8) 0.71 231 (21.7) 380 (23.2) 0.37 
Previous STEMI- n (%) 396 (16.2%) 184 (5.0) <
0.001 
219 (15.9) 101 (5) <
0.001 
177 (16.6) 83 (5.1) <
0.001 
Previous PCI – n (%) 500 (20.5) 269 (7.4) <
0.001 
276 (20.1) 154 (7.6) <
0.001 
224 (21) 115 (7) <
0.001 
Previous CABG - n (%) 67 (2.7) 40 (1.1) <
0.001 
30 (2.2) 27 (1.3) 0.08 37 (3.5) 13 (0.8) <
0.001 
Referral to Primary PCI 
Hospital          
Ambulance (from community) 
– n (%) 
1304 (53.4) 2057 (56.3) 0.027 717 (52.1) 1091 (54.2) 0.25 587 (55.1) 966 (58.9) 0.049 
Time delays          








180 [120–300] 0.009 210 
[135–385] 
195 [125–330] 0.006 
Total Ischemia time > 12 h – n 
(%) 
270 (11.1) 348 (9.5) 0.051 123 (8.9) 184 (9.1) 0.85 147 (13.8) 164 (10.0) 0.003 
Door-to-balloon time, median 
[25–75th] 
40 [25–60] 35 [22–60] <
0.001 
38 [25–60] 32 [21–60] 0.006 40 [28–63] 35 [24–60] <
0.001 
Door-to-balloon time > 30 min 
(%)– n (%) 
1490 (61.1) 1936 [53] <
0.001 
800 (58.2) 1038 (51.6) <
0.001 
690 (64.8) 898 (54.8) <
0.001 
Clinical Presentation          
Anterior STEMI – n (%) 1079 (44.2) 1695 (46.4) 0.093 607 (44.1) 941 (46.7) 0.14 472(44.3) 754 [46] 0.41 
Out-of-hospital cardiac arrest – 
n (%) 
134 (5.5) 280 (7.7) 0.001 77 (5.6) 148 (7.3) 0.045 57 (5.3) 132 (8) 0.007 
Cardiogenic shock– n (%) 198 (8.1) 314 (8.6) 0.51 118 (8.6) 147 (7.3) 0.17 80 (7.5) 167 (10.2) 0.02 
Rescue PCI for failed 
thrombolysis – n (%) 
93 (3.8) 126 (3.4) 0.46 51 (3.7) 73 (3.6) 0.93 42 (3.9) 53 (3.2) 0.34 
*Mann-Whitney test 
CAD = Coronary Artery Disease; STEMI = ST-segment Elevation Myocardial Infarction; PCI = Percutaneous Coronary Intervention; CABG 0 Coronary Artery Bypass 
Graft; 
Fig. 1. Bar graphs show in-hospital mortality in overall population, in 2019 
and 2020 patients according to chronic RASI therapy at admission. 
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among STEMI patients already at short-term follow-up, when the 
treatment was initiated within the first weeks after the event [15,16]. 
However, insights from animal studies suggest that ACE2 inhibition 
might play a negative prognostic role of ACE2 inhibition in COVID-19 
patients. In fact, the ACE2 enzyme is a cell membrane protein, that is 
used by the SARS-CoV-2 virus to enter cells [2,17]. Given the increased 
ACE2 expression in cardiovascular and renal systems shown in experi-
mental studies with angiotensin receptor blockers (ARBs) and an ACE 
inhibitor (ACEI), concerns have been raised that these drugs might 
augment the SARS-CoV-2 infection and the severity of the coronavirus 
disease in patients with arterial hypertension and CVD, receiving these 
drugs [18–20]. 
The use of ACEI/ARBs in patients with COVID-19 is controversial in 
Fig. 2. Bar graphs show the prevalence of SARS-CoV2 infection in patients 
treated in 2020 according to chronic RASI therapy at admission (left graph) and 
in-hospital RASI (right graph). 
Table 2 
Baseline demographic and clinical characteristics according to in-hospital RASI therapy.   
OVERALL POPULATION 
(N = 5388)  
YEAR 2019 (N = 2877)  YEAR 2020 (N = 2511)  
RASI 
(n = 4080) 
No RASI 
(n = 1308) 
P value RASI 
(n = 2187) 
No RASI 2019 
(n = 680) 
P value RASI 
(n = 1883) 
No RASI 2020 
(n = 628) 
P value 
Age (median, IQR) 63 [55–72] 66 [57–75] < 0.001 63 [55–72] 67 [57–75] < 0.001 63 [54–71] 65 [57–75] < 0.001 
Age > 75 year – n. (%) 795 (19.5) 338 (25.8) < 0.001 442 (20.1) 177 (26) 0.001 353 (18.7) 161 (25.6) < 0.001 
Male gender – n. (%) 3047 (74.7) 917 (70.1) 0.001 1603 (73) 482 (70.9) 0.30 1444 (76.7) 435 (69.3) < 0.001 
Diabetes Mellitus- n (%) 872 (21.4) 310 (23.7) 0.08 465 (21.2) 176 (25.9) 0.01 407 (21.6) 134 (21.3) 0.91 
Hypertension- n (%) 2295 (53.6) 700 (53.5) 0.08 1256 (57.2) 377 (55.4) 0.45 1039 (55.2) 323 (51.4) 0.11 
Hypercholesterolemia - n (%) 1799 (44.1) 509 (38.9) 0.001 957 (43.6) 263 (38.7) 0.03 842 (44.7) 246 (39.2) 0.02 
Active Smokers– n (%) 1765 (43.3) 507 (38.8) 0.004 952 (43.3) 259 (38.1) 0.02 813 (43.2) 248 (39.5) 0.11 
Family History of CAD - n (%) 961 (23.6) 259 (19.8) 0.005 519 (23.6) 141 (20.7) 0.13 442 (23.5) 118 (18.8) 0.02 
Previous STEMI- n (%) 390 (9.6) 108 (8.3) 0.17 211 (9.6) 51 (7.5) 0.11 179 (9.5) 57 (9.1) 0.81 
Previous PCI – n (%) 530 (13) 138 (10.6) 0.01 247 (12.5) 81 (11.9) 0.74 256 (13.6) 57 [91] 0.03 
Previous CABG - n (%) 59 (1.4) 29 (2.2) 0.06 28 (1.3) 14 (2.1) 0.14 31 (1.6) 15 (2.4) 0.23 
Referral to Primary PCI 
Hospital          
Ambulance (from community) 
– n (%) 
2247 (55.1) 682 (52.1) 0.06 1169 (53.2) 339 (44.9) 0.14 1078 (52.7) 343 (54.6) 0.27 
Time delays          




191 [125–330] 0.76 190 
[120–313] 
180 [120–289] 0.18 200 
[127–345] 
210 [130–380] 0.36 
Total Ischemia time > 12 h – n 
(%) 
425 (10.4) 127 (9.7) 0.50 207 (9.4) 53 (7.8) 0.22 218 (11.6) 74 (11.8) 0.89 
Door-to-balloon time, median 
[25–75th] 
35 [25–60] 40 [25–68] < 0.001 35 [24–60] 40 [25–68] < 0.001 37 [25–60] 40 [25–69] 0.007 
Door-to-balloon time          
>30 min– n (%) 2259 (55.4) 816 (62.4) < 0.001 1184 (53.9) 424 (62.4) < 0.001 1075 (57.1) 392 (62.4) 0.002 
Clinical Presentation          
Anterior STEMI– n (%) 1922 (47.1) 554 (42.2) 0.003 1043 (47.5) 287 (42.2) 0.02 879 (46.7) 267 (42.5) 0.07 
Out-of-hospital cardiac arrest – 
n (%) 
226 (5.5) 122 (9.3) < 0.001 119 (5.4) 55 (8.1) 0.02 107 (5.7) 67 (10.7) < 0.001 
Cardiogenic shock– n (%) 223 (5.5) 224 (17.1) < 0.001 109 (5) 106 (15.6) < 0.001 114 (6.1) 118 (18.8) < 0.001 
Rescue PCI for failed 
thrombolysis – n (%) 
148 (3.6) 48 (3.7) 0.93 77 (3.5) 26 (3.8) 0.72 71 (3.8) 22 (3.5) 0.81 
*Mann-Whitney test 
CAD = Coronary Artery Disease; STEMI = ST-segment Elevation Myocardial Infarction; PCI = Percutaneous Coronary Intervention; CABG 0 Coronary Artery Bypass 
Graft; 
Fig. 3. Bar graphs show in-hospital mortality in overall population, in 2019 
and 2020 patients according to in-hospital RASI therapy. 
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part due to the early reports from China, suggesting that COVID-19 
patients with hypertension have worse outcomes [21–25]. The ana-
lyses were crude and confounding factors were present that were also 
associated with hypertension, such as older age and cardiovascular 
disease. In patients with cardiovascular disease, COVID-19 is associated 
with substantial mortality, and clarification of confounding by disease 
or indication is crucial. In fact, several additional studies have shown no 
harmful effects or even beneficial effects from RASI therapy [6–8]. 
Mangia et al. [26] carried out a population-based case–control study 
in the Lombardy region of Italy. A total of 6272 case patients in whom 
infection with severe acute respiratory syndrome coronavirus 2 (SAR-
S-CoV-2) was confirmed between February 21 and March 11, 2020, were 
matched with 30,759 beneficiaries of the Regional Health Service 
(controls) according to sex, age, and municipality of residence. Due to 
the higher prevalence of cardiovascular disease, the use of ACE in-
hibitors and ARBs was more frequent among patients with COVID-19 
than among control subjects. However, there was no evidence that 
ACE inhibitors or ARBs affected the risk of COVID-19. Li et al. [6] 
examined a case series from hospitals in Wuhan, China, and found no 
association between RASI and COVID-19. Similar results have been 
described from North America [10,11]. Reynolds et al. [27] studied 
patients with COVID-19 and hypertension and found no significant 
difference in COVID-19 outcomes with RASI use as compared to other 
antihypertensive drugs. The results have been confirmed in population 
studies conducted in Spain [7] and Denmark [8]. In both analyses, RASI 
were associated with higher mortality that disappeared after adjustment 
for confounding factors. The authors concluded that the prior use of 
ACEI/ARBs was not significantly associated with COVID-19 diagnosis 
among patients with hypertension or with mortality or severe disease 
among patients diagnosed as having COVID-19. The absence of any 
harmful effect of ACE-Inhibitors has been recently confirmed in several 
meta-analysis [28,29]. 
However, so far, no data have been reported in patients with an acute 
STEMI, representing a population with a very high adverse event risk 
and guideline-recommended RASI use in the majority of patients. 
Our report is the first study focused on STEMI patients undergoing 
mechanical reperfusion, including more than 6000 patients treated with 
primary PCI. We found that chronic RASI at admission did not affect the 
prevalence of SARSCoV2 infection and was associated with lower mor-
tality and cardiogenic shock at presentation. Furthermore, in-hospital 
RASI therapy was associated with a significantly lower mortality, and 
a lower prevalence of SARSCoV2 infection, but showed no significant 
relationship with the survival of infected patients. Therefore, the present 
study confirms the overall mortality benefit of RASI in patients with 
STEMI, and additionally it does not suggest a link between RASI therapy 
and COVID-19 susceptibility or subsequent worse outcomes in case of 
COVID-19 infection. 
Professional societies have issued position statements that ACEI/ 
ARBs should not be discontinued [5], statements that this study sup-
ports. Several randomized studies have been initiated in various settings 
of COVID-19 (hospitalized and outpatient) and for both ACEIs and ARBs 
as well [30,31]. In the recent randomized BRACE-CORONA Trial [32], 
659 patients with chronic RASI therapy at admission and confirmed 
diagnosis of COVID-19 were randomly assigned to a temporary 30-day 
suspension or continuation of RASI therapy. A similar 30-day mortal-
ity (2.8% vs 2.7%) was observed between the two groups. Waiting for 
the results of further randomized trials, that will definitively provide 
information on the harmful or beneficial effects on the occurrence of 
COVID and its mortality rates, RASI therapy should still be prescribed 
and not interrupted, especially among patients suffering from hyper-
tension, heart failure or STEMI, clinical settings in which the greatest 
benefits in outcome may be expected. 
5. Limitations 
This study, which assessed data from 77 high-volume European 
primary PCI centers, is limited by its retrospective, non-randomized 
design. As it may be expected, patients on RASI therapy differed from 
the other patients in age and some comorbidities, and displayed a more 
composite cardiovascular history, with potential negative impact on the 
prognosis. Nevertheless, these patients could also have been the ones 
with previous regular hospital visits and with good compliance to 
medication. However, since we included an all-comers population, we 
expect a balancing between these two opposite potential biases and 
moreover we adjusted the findings for all known confounding factors. 
Furthermore, our research was conducted during a pandemic emer-
gency, which was a challenge and expected to encounter some missing 
data. Nevertheless, considering all adversities, the proportion of patients 
with missing data regarding in-hospital RASI therapy was acceptable. As 
we did not collect information on the type and dosage of RASI, we 
cannot perform a further in-depth assessment of prognostic implica-
tions. Although in 2019 and 2020 similar rates of RASI prescription were 
observed, we cannot exclude that during hospitalization RASI might 
have been less often prescribed among patients with (actual or pre-
sumed) SARS-CoV2 positivity, because of the fear of a potential negative 
impact of RASI on surviving COVID-19. In fact, even though the results 
of the molecular swab were generally available only after PCI, therefore 
not affecting procedural indications, such information could have, 
instead, potentially conditioned the RASI prescription after the inter-
vention. Therefore, the present report provides a real-life picture of the 
management of STEMI patients during the pandemic. In addition, acute 
kidney failure, heart failure, and hypotension might have represented 
severe comorbidities, preventing the introduction of RASI therapy dur-
ing hospitalization and negatively affecting the prognosis. Unfortu-
nately, these data were not routinely collected and are, therefore, not 
available. However, these factors could have biased the evaluation of the 
prognostic implications of initiation of RASI therapy during hospitali-
zation rather than the prognostic impact chronic RASI at admission, that 
represented our main primary analysis. In addition, although our data-
base comprised almost 5400 STEMI patients with known in-hospital 
pharmacological therapy and clinical outcome following mechanical 
reperfusion therapy, the evaluation of the prognostic impact of RASI 
therapy among SARS-CoV2-positive patients was limited due to the 
relatively low prevalence of the infection, and neither we could evaluate 
the incidence of respiratory complications in these patients. 
Finally, we included only patients undergoing primary PCI, 
excluding those who died before hospital admission or prior to angi-
ography, and STEMI patients managed conservatively. Therefore, 
caution should be exercised in the interpretation the prognostic impli-
cations of our results. 
6. Conclusions 
This is the first study investigating the prognostic impact of RASI 
therapy in STEMI patients undergoing mechanical reperfusion during 
COVID-19 pandemic. We found that chronic RASI therapy at admission 
and RASI therapy during hospitalization were associated with a signif-
icant reduction in mortality, without any negative effect on SARSCoV2 
infection or survival among SARSCoV2 positive patients. Therefore, 
waiting for future randomized trials, RASI should not be suspended or 
omitted, unless contraindicated, among STEMI patients undergoing 
mechanical reperfusion, even in case of SARSCoV2 infection. 
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